1. Academic Validation
  2. A carvedilol analogue, VK-II-86, prevents hypokalaemia-induced ventricular arrhythmia through novel multi-channel effects

A carvedilol analogue, VK-II-86, prevents hypokalaemia-induced ventricular arrhythmia through novel multi-channel effects

  • Br J Pharmacol. 2022 Jun;179(11):2713-2732. doi: 10.1111/bph.15775.
Victoria M Robinson 1 2 Izzeddin Alsalahat 1 Sally Freeman 1 Charles Antzelevitch 2 3 4 Héctor Barajas-Martinez 2 Luigi Venetucci 1
Affiliations

Affiliations

  • 1 Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • 2 Cardiovascular Sciences, Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.
  • 3 Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • 4 Lankenau Heart Institute, Lankenau Medical Center, Main Line Health, Wynnewood, Pennsylvania, USA.
Abstract

Background and purpose: QT prolongation and intracellular CA2+ loading with diastolic CA2+ release via ryanodine receptors (RyR2) are the predominant mechanisms underlying hypokalaemia-induced ventricular arrhythmia. We investigated the antiarrhythmic actions of two RyR2 inhibitors: dantrolene and VK-II-86, a carvedilol analogue lacking antagonist activity at β-adrenoceptors, in hypokalaemia.

Experimental approach: Surface ECG and ventricular action potentials (APs) were recorded from whole-heart murine Langendorff preparations. Ventricular arrhythmia incidence was compared in hearts perfused with low [K+ ], and those pretreated with dantrolene or VK-II-86. Whole-cell patch clamping was used in murine and canine ventricular cardiomyocytes to study effects of dantrolene and VK-II-86 on AP parameters in low [K+ ] and effects of VK-II-86 on the inward rectifier current (IK1 ), late sodium current (INa_L ) and the L-type CA2+ current (ICA ). Effects of VK-II-86 on IKr were investigated in transfected HEK-293 cells. A fluorogenic probe quantified the effects of VK-II-86 on oxidative stress in hypokalaemia.

Key results: Dantrolene reduced the incidence of ventricular arrhythmias induced by low [K+ ] in explanted murine hearts by 94%, whereas VK-II-86 prevented all arrhythmias. VK-II-86 prevented hypokalaemia-induced AP prolongation and depolarization but did not alter AP parameters in normokalaemia. Hypokalaemia was associated with decreased IK1 and IKr , and increased INa-L , and ICA . VK-II-86 prevented all hypokalaemia-induced changes in ion channel activity and oxidative stress.

Conclusions and implications: VK-II-86 prevents hypokalaemia-induced arrhythmogenesis by normalizing calcium homeostasis and repolarization reserve. VK-II-86 may provide an effective treatment in hypokalaemia and Other arrhythmias caused by delayed repolarization or CA2+ overload.

Keywords

animal models of human disease; arrhythmias; basic science research; electrophysiology; pharmacology.

Figures
Products